Rearmed Bifunctional Chelating Ligand for 225Ac/155Tb Precision-Guided Theranostic Radiopharmaceuticals─H4noneunpaX
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2023/09/22
-
Journal
-
Indian UGC (journal)
-
Refrences69
-
Citations3
-
Luke Wharton Medicinal Inorganic Chemistry Group, Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, British Columbia V6T 1Z1, CanadaLife Sciences Division, TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, Canada ORCID
-
Hua Yang Life Sciences Division, TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, CanadaDepartment of Chemistry, Simon Fraser University, Burnaby, British Columbia V5A 1S6, Canada ORCID
-
María de Guadalupe Jaraquemada-Peláez Medicinal Inorganic Chemistry Group, Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, British Columbia V6T 1Z1, CanadaMolecular Oncology Group, British Columbia Cancer Research Centre (BCCRC), Vancouver, British Columbia V5Z 1L3, Canada ORCID
-
Helen Merkens Molecular Oncology Group, British Columbia Cancer Research Centre (BCCRC), Vancouver, British Columbia V5Z 1L3, Canada
-
Gokce Engudar Life Sciences Division, TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, Canada
-
Aidan Ingham Life Sciences Division, TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, Canada
-
Helena Koniar Life Sciences Division, TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, CanadaDepartment of Physics and Astronomy, University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada
-
Valery Radchenko Life Sciences Division, TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, CanadaDepartment of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, British Columbia V6T 1Z1, Canada
-
Peter Kunz Life Sciences Division, TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, Canada
-
Paul Schaffer Life Sciences Division, TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, CanadaDepartment of Chemistry, Simon Fraser University, Burnaby, British Columbia V5A 1S6, CanadaDepartment of Radiology, University of British Columbia, Vancouver, British Columbia V5Z 1M9, Canada ORCID
-
François Bénard Molecular Oncology Group, British Columbia Cancer Research Centre (BCCRC), Vancouver, British Columbia V5Z 1L3, CanadaDepartment of Radiology, University of British Columbia, Vancouver, British Columbia V5Z 1M9, Canada ORCID
-
Chris Orvig Medicinal Inorganic Chemistry Group, Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, British Columbia V6T 1Z1, Canada ORCID
Cite
Wharton, Luke, et al. “Rearmed Bifunctional Chelating Ligand for 225Ac 155Tb Precision-Guided Theranostic Radiopharmaceuticals─H4noneunpaX”. Journal of Medicinal Chemistry, vol. 66, no. 19, 2023, pp. 13705-30, https://doi.org/10.1021/acs.jmedchem.3c01151.
Wharton, L., Yang, H., Jaraquemada-Peláez, M. de G., Merkens, H., Engudar, G., Ingham, A., Koniar, H., Radchenko, V., Kunz, P., Schaffer, P., Bénard, F., & Orvig, C. (2023). Rearmed Bifunctional Chelating Ligand for 225Ac/155Tb Precision-Guided Theranostic Radiopharmaceuticals─H4noneunpaX. Journal of Medicinal Chemistry, 66(19), 13705-13730. https://doi.org/10.1021/acs.jmedchem.3c01151
Wharton, Luke, Hua Yang, María de Guadalupe Jaraquemada-Peláez, Helen Merkens, Gokce Engudar, Aidan Ingham, Helena Koniar, et al. “Rearmed Bifunctional Chelating Ligand for 225Ac 155Tb Precision-Guided Theranostic Radiopharmaceuticals─H4noneunpaX”. Journal of Medicinal Chemistry 66, no. 19 (2023): 13705-30. https://doi.org/10.1021/acs.jmedchem.3c01151.
Wharton L, Yang H, Jaraquemada-Peláez M de G, Merkens H, Engudar G, Ingham A, et al. Rearmed Bifunctional Chelating Ligand for 225Ac/155Tb Precision-Guided Theranostic Radiopharmaceuticals─H4noneunpaX. Journal of Medicinal Chemistry. 2023;66(19):13705-30.
Journal Categories
Medicine
Therapeutics
Pharmacology
Science
Chemistry
Science
Chemistry
Analytical chemistry
You May Also Like
Refrences
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| Title | Annali di Chimica | 1999 | ||
| 10.1007/978-1-4615-6761-5 | 1982 | |||
| Handbook on the Physics and Chemistry of Rare Earths | 2022 | |||
| The Mouse in Biomedical Research | 1983 | |||
| Chelating the Alpha Therapy Radionuclides 225Ac3+ and 213Bi3+ with 18-Membered Macrocyclic Ligands Macrodipa and Py-Macrodipa | Inorganic Chemistry |
| 14 | 2021 |
Citations
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
Towards Effective Targeted Alpha Therapy for Neuroendocrine Tumours: A Review | Pharmaceuticals |
| 2024 | |
| Diagnostic and Therapeutic Radiopharmaceuticals: A “Hot” Topic | Journal of Medicinal Chemistry |
| 1 | 2023 |
| Diagnostic and Therapeutic Radiopharmaceuticals: A “Hot” Topic | ACS Pharmacology & Translational Science |
| 2023 |
Citations Analysis
The category
Medicine: Therapeutics. Pharmacology 2
is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Diagnostic and Therapeutic Radiopharmaceuticals: A “Hot” Topic and was published in 2023. The most recent citation comes from a 2024 study titled Towards Effective Targeted Alpha Therapy for Neuroendocrine Tumours: A Review. This article reached its peak citation in 2023, with 2 citations. It has been cited in 3 different journals, 33% of which are open access. Among related journals, the Pharmaceuticals cited this research the most, with 1 citations. The chart below illustrates the annual citation trends for this article.